Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5690289 | 0.84 | TMEM97 (0.53) | TMEM97SIGMAR1CXCR3KMT2AMAPT | |
| SCHEMBL5690806 | 0.83 | TMEM97 (0.59) | TMEM97SIGMAR1CXCR3KMT2AMAPT | |
| SCHEMBL5689952 | 0.81 | CXCR3 (0.57) | TMEM97SIGMAR1CXCR3KMT2AMAPT | |
| SCHEMBL5446306 | 0.81 | TMEM97 (0.67) | TMEM97SIGMAR1CXCR3HTR1AHTR1D | |
| SCHEMBL5690320 | 0.81 | ENPP2 (0.57) | TMEM97SIGMAR1POLBCXCR3KMT2A | |
| SCHEMBL14571502 | 0.80 | CXCR3 (0.55) | TMEM97SIGMAR1POLBCXCR3ALDH1A1 | |
| SCHEMBL5690040 | 0.78 | ERCC1 (0.58) | TMEM97SIGMAR1POLBCXCR3MAPT | |
| SCHEMBL14591397 | 0.76 | CXCR3 (0.56) | TMEM97SIGMAR1CXCR3USP2TSHR | |
| SCHEMBL5861502 | 0.76 | TMEM97 (0.58) | TMEM97SIGMAR1CXCR3KMT2AALDH1A1 | |
| SCHEMBL5861550 | 0.74 | TMEM97 (0.59) | TMEM97SIGMAR1CXCR3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | claimed |
| EP-1641760-A2 | NOVEL TETRAHYDROQUINOLINES | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004108682-A2 | TETRAHYDROISOQUINOLINES AS ANTAGONISTS OF THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | claimed |
| US-7101881-B2 | Tetrahydroquinolines | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1641760-A2 | NOVEL TETRAHYDROQUINOLINES | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004108682-A2 | TETRAHYDROISOQUINOLINES AS ANTAGONISTS OF THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254193-A1 | Novel tetrahydroquinolines | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254193-A1 | Novel tetrahydroquinolines | HTR5A, SLC18A2, HTR3B | TMEM97 264/4885SIGMAR1 545/4885POLB 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.